Maciej J Zamek-Gliszczynski

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. pmc Relationship between drug/metabolite exposure and impairment of excretory transport function
    Maciej J Zamek-Gliszczynski
    Drug Disposition, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Drug Metab Dispos 37:386-90. 2009
  2. doi request reprint Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics
    J William Higgins
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Drug Metab Dispos 40:1170-7. 2012
  3. doi request reprint Highlights from the International Transporter Consortium second workshop
    M J Zamek-Gliszczynski
    Drug Disposition, Lilly Research Laboratories, Indianapolis, Indiana, USA
    Clin Pharmacol Ther 92:553-6. 2012
  4. doi request reprint Minor compensatory changes in SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats do not detract from their utility in the study of transporter-mediated pharmacokinetics
    Maciej J Zamek-Gliszczynski
    Drug Disposition and Toxicology, Lilly Research Laboratories, Indianapolis, IN, USA
    Drug Metab Dispos 41:1174-8. 2013
  5. doi request reprint Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure
    Maciej J Zamek-Gliszczynski
    Drug Disposition Pharmacokinetics Pharmacodynamics, Lilly Research Laboratories, Indianapolis, Indiana, USA
    Drug Metab Dispos 41:714-26. 2013
  6. doi request reprint Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics
    Maciej J Zamek-Gliszczynski
    Lilly Corporate Center, Indianapolis, IN 46285, USA
    Drug Metab Dispos 40:1825-33. 2012
  7. doi request reprint How well do lipophilicity parameters, MEEKC microemulsion capacity factor, and plasma protein binding predict CNS tissue binding?
    Maciej J Zamek-Gliszczynski
    Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Pharm Sci 101:1932-40. 2012
  8. doi request reprint Efflux transport is an important determinant of ethinylestradiol glucuronide and ethinylestradiol sulfate pharmacokinetics
    Maciej J Zamek-Gliszczynski
    Lilly Corporate Center, Indianapolis, IN 46285, USA
    Drug Metab Dispos 39:1794-800. 2011
  9. doi request reprint Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs
    Maciej J Zamek-Gliszczynski
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Pharm Sci 100:2498-507. 2011
  10. ncbi request reprint Metformin sinusoidal efflux from the liver is consistent with negligible biliary excretion and absence of enterohepatic cycling
    Maciej J Zamek-Gliszczynski
    Drug Disposition, Lilly Research Laboratories, Indianapolis, Indiana
    Drug Metab Dispos 41:1967-71. 2013

Collaborators

Detail Information

Publications12

  1. pmc Relationship between drug/metabolite exposure and impairment of excretory transport function
    Maciej J Zamek-Gliszczynski
    Drug Disposition, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Drug Metab Dispos 37:386-90. 2009
    ....
  2. doi request reprint Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics
    J William Higgins
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Drug Metab Dispos 40:1170-7. 2012
    ..These findings challenge the presumption that systemic OCT inhibition will affect metformin pharmacology...
  3. doi request reprint Highlights from the International Transporter Consortium second workshop
    M J Zamek-Gliszczynski
    Drug Disposition, Lilly Research Laboratories, Indianapolis, Indiana, USA
    Clin Pharmacol Ther 92:553-6. 2012
    ..The outcome of the workshop will be a series of white papers targeted for publication in 2013...
  4. doi request reprint Minor compensatory changes in SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats do not detract from their utility in the study of transporter-mediated pharmacokinetics
    Maciej J Zamek-Gliszczynski
    Drug Disposition and Toxicology, Lilly Research Laboratories, Indianapolis, IN, USA
    Drug Metab Dispos 41:1174-8. 2013
    ....
  5. doi request reprint Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure
    Maciej J Zamek-Gliszczynski
    Drug Disposition Pharmacokinetics Pharmacodynamics, Lilly Research Laboratories, Indianapolis, Indiana, USA
    Drug Metab Dispos 41:714-26. 2013
    ..In conclusion, LY2090314 was rapidly cleared by extensive metabolism with negligible circulating metabolite exposures due to biliary excretion of metabolites into feces with no apparent intestinal reabsorption...
  6. doi request reprint Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics
    Maciej J Zamek-Gliszczynski
    Lilly Corporate Center, Indianapolis, IN 46285, USA
    Drug Metab Dispos 40:1825-33. 2012
    ....
  7. doi request reprint How well do lipophilicity parameters, MEEKC microemulsion capacity factor, and plasma protein binding predict CNS tissue binding?
    Maciej J Zamek-Gliszczynski
    Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Pharm Sci 101:1932-40. 2012
    ....
  8. doi request reprint Efflux transport is an important determinant of ethinylestradiol glucuronide and ethinylestradiol sulfate pharmacokinetics
    Maciej J Zamek-Gliszczynski
    Lilly Corporate Center, Indianapolis, IN 46285, USA
    Drug Metab Dispos 39:1794-800. 2011
    ..In conclusion, altered efflux transport resulted in major alterations of EEG and EES pharmacokinetics, highlighting transport as a potential site of DDIs with EE conjugates...
  9. doi request reprint Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs
    Maciej J Zamek-Gliszczynski
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Pharm Sci 100:2498-507. 2011
    ..The presented methodology establishes an experimental protocol for definitive PB measurement, which enables quantitative determination of low Fu values, necessary for navigation of new regulatory guidances in clinical drug development...
  10. ncbi request reprint Metformin sinusoidal efflux from the liver is consistent with negligible biliary excretion and absence of enterohepatic cycling
    Maciej J Zamek-Gliszczynski
    Drug Disposition, Lilly Research Laboratories, Indianapolis, Indiana
    Drug Metab Dispos 41:1967-71. 2013
    ..These studies demonstrate that despite similar magnitude of metformin liver and kidney distribution, metformin biliary excretion is negligible due to predominant sinusoidal efflux from the liver...
  11. doi request reprint Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein
    J William Higgins
    Drug Disposition J W H, J Q B, A B K, M J Z G and Global Statistical Sciences J R M, Lilly Research Laboratories, Indianapolis, Indiana and Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina J K F, P C S, M J Z G
    Drug Metab Dispos 42:182-92. 2014
    ..7-fold, but only after correcting for human/humanized mouse liver relative protein expression factor (OATP1B1 = 2.2, OATP1B3 = 0.30). ..
  12. ncbi request reprint Investigational small-molecule drug selectively suppresses constitutive CYP2B6 activity at the gene transcription level: physiologically based pharmacokinetic model assessment of clinical drug interaction risk
    Maciej J Zamek-Gliszczynski
    Drug Disposition, Lilly Research Laboratories, Indianapolis, Indiana
    Drug Metab Dispos 42:1008-15. 2014
    ..However, simulations showed that observed CYP2B6 suppression could be clinically relevant for a drug with different pharmacokinetic properties from LY2090314. ..